Nothing Special   »   [go: up one dir, main page]

CR20170195A - Espiro-tiazolonas - Google Patents

Espiro-tiazolonas

Info

Publication number
CR20170195A
CR20170195A CR20170195A CR20170195A CR20170195A CR 20170195 A CR20170195 A CR 20170195A CR 20170195 A CR20170195 A CR 20170195A CR 20170195 A CR20170195 A CR 20170195A CR 20170195 A CR20170195 A CR 20170195A
Authority
CR
Costa Rica
Prior art keywords
receptor
act
disorders
tiazolonas
espiro
Prior art date
Application number
CR20170195A
Other languages
English (en)
Inventor
Bernhard Fasching
Cosimo Dolente
Patrick Schnider
Valerie Runtz-Schmitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170195A publication Critical patent/CR20170195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona espiro-tiazolonas, que actúan como moduladores del receptor V1a, y en particular, como antagonistas del receptor V1a, su fabricación, a composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los presentes compuestos son útiles como agentes terapéuticos que actúan de manera periférica y central en condiciones de secreción inadecuada de vasopresina, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos del espectro autista, esquizofrenia, comportamiento agresivo y trastornos del sueño por cambio de fase, en particular, descompensación horaria.
CR20170195A 2014-11-14 2015-11-11 Espiro-tiazolonas CR20170195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193294 2014-11-14
PCT/EP2015/076278 WO2016075181A1 (en) 2014-11-14 2015-11-11 Spiro-thiazolones

Publications (1)

Publication Number Publication Date
CR20170195A true CR20170195A (es) 2017-05-31

Family

ID=51904773

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170195A CR20170195A (es) 2014-11-14 2015-11-11 Espiro-tiazolonas

Country Status (21)

Country Link
US (1) US10092551B2 (es)
EP (1) EP3218381B1 (es)
JP (1) JP6629855B2 (es)
KR (1) KR20170084047A (es)
CN (1) CN107001382B (es)
AR (1) AR102633A1 (es)
AU (1) AU2015345102A1 (es)
BR (1) BR112017007363A2 (es)
CA (1) CA2963188A1 (es)
CL (1) CL2017001231A1 (es)
CO (1) CO2017002963A2 (es)
CR (1) CR20170195A (es)
EA (1) EA201790919A1 (es)
IL (1) IL250999A0 (es)
MX (1) MX2017006294A (es)
PE (1) PE20170671A1 (es)
PH (1) PH12017500891A1 (es)
SG (1) SG11201703604VA (es)
TW (1) TW201625642A (es)
WO (1) WO2016075181A1 (es)
ZA (1) ZA201701914B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608718A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
CA2670674A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
BRPI0806538A2 (pt) * 2007-01-12 2014-04-22 Hoffmann La Roche Derivados de glicinamida de espiropiperidina
PE20110537A1 (es) * 2008-11-13 2011-08-04 Hoffmann La Roche ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a
JP2016513112A (ja) * 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター

Also Published As

Publication number Publication date
WO2016075181A1 (en) 2016-05-19
CL2017001231A1 (es) 2018-01-12
TW201625642A (zh) 2016-07-16
CN107001382B (zh) 2019-10-25
US10092551B2 (en) 2018-10-09
SG11201703604VA (en) 2017-06-29
CA2963188A1 (en) 2016-05-19
JP2017533933A (ja) 2017-11-16
MX2017006294A (es) 2017-08-21
ZA201701914B (en) 2018-12-19
CN107001382A (zh) 2017-08-01
CO2017002963A2 (es) 2017-07-19
EA201790919A1 (ru) 2017-08-31
EP3218381B1 (en) 2019-01-23
IL250999A0 (en) 2017-04-30
AR102633A1 (es) 2017-03-15
AU2015345102A1 (en) 2017-03-30
KR20170084047A (ko) 2017-07-19
EP3218381A1 (en) 2017-09-20
BR112017007363A2 (pt) 2017-12-19
JP6629855B2 (ja) 2020-01-15
PE20170671A1 (es) 2017-05-22
PH12017500891A1 (en) 2017-11-06
US20170246153A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
DOP2017000298A (es) Reguladores de nrf2
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
CL2015002222A1 (es) Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos.
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
ECSP16074478A (es) Compuestos novedosos
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CR20160215A (es) Espiro-oxazolonas
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
CO2018005354A2 (es) Derivados novedosos de diamino piridina
MX2016009501A (es) Espiro-oxazolonas.
CR20170195A (es) Espiro-tiazolonas
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete
UY34752A (es) Agentes para el control de la chinche del eucalipto
UY34664A (es) Derivados de piridona y piridazinona como antagonistas de mch-1r, composiciones farmacéuticas y sus usos